DoubleChecks

What was claimed

New study shows 84.4% clinical benefit rate for Ivermectin and Mebendazole in cancer with nearly half of patients reporting disappearance (presented as potential cure).

Our verdict

Inaccurate

The study is observational and self-reported, and external fact checks say it cannot demonstrate that ivermectin or mebendazole improves cancer outcomes. That is not evidence of a cure. An uncontrolled, self‑reported observational study cannot establish cure or efficacy; independent verification and randomized controlled trials are required to demonstrate a treatment cures cancer.

1 of 3 AI systems agree21 sources citedChecked Sep 27, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

The study supports presenting the treatment as a potential cure for cancer.

Incorrect93%
All 2 AIs agree

These results demonstrate ivermectin and mebendazole are cures for cancer.

Incorrect93%
1 AI checked

Study demonstrates clinical efficacy of this combination for cancer

Misleading90%
1 AI checked

Nearly half of patients reported disappearance (presented as potential cure).

Misleading92%
All 3 AIs agree

A new study shows an 84.4% clinical benefit rate for ivermectin and mebendazole in cancer.

Verified95%
All 3 AIs agree

Verified against 21 sources

pubmed.ncbi.nlm.nih.govzenodo.orgyahoo.comtwc.healthonedaymd.comclyr.healthexpose-news.comus.headtopics.comx.comus.headtopics.combreitbart.combreitbart.comsciencebasedmedicine.orgx.comthegatewaypundit.comyahoo.commakisw.substack.comfr.news.yahoo.comlessentiel.lutribtoday.commedpagetoday.com

Detailed Analysis

The core numbers in the claim are supported by the published study: 84.4% clinical benefit and 48.4% reporting tumor regression or no evidence of disease. But the wording is misleading because the study was a real-world, self-reported observational cohort, not evidence of a proven cancer cure, and external fact checks note major bias and lack of independent verification.

Why this verdict

  • The core numbers in the claim are supported by the published study: 84.4% clinical benefit and 48.4% reporting tumor regression or no evidence of disease.
  • But the wording is misleading because the study was a real-world, self-reported observational cohort, not evidence of a proven cancer cure, and external fact checks note major bias and lack of independent verification.

Claims checked

The study supports presenting the treatment as a potential cure for cancer.

Incorrect93%
The study is observational and self-reported, and external fact checks say it cannot demonstrate that ivermectin or mebendazole improves cancer outcomes. That is not evidence of a cure.

This claim may mislead readers without added context.

Nearly half of patients reported disappearance.

Misleading95%
The study reports 48.4% said they had tumor regression or no evidence of disease. That is not the same as confirmed disappearance, because it is self-reported and combines two different outcomes.

This claim may mislead readers without added context.

A new study shows an 84.4% clinical benefit rate for ivermectin and mebendazole in cancer.

Verified98%
The PubMed record reports a Clinical Benefit Ratio of 84.4% with a 95% confidence interval of 77.0% to 89.8%.

What other AI think

The claim selectively presents data from a self-reported observational study while omitting critical context that fundamentally changes its meaning. The 84.4% figure is accurate but misleading without noting concurrent therapies and low completion rates. Most problematically, framing results as a "potential cure" contradicts the study's own conclusion that findings are "hypothesis-generating" and contradicts expert consensus that clinical evidence is insufficient.

Why this verdict

  • The claim selectively presents data from a self-reported observational study while omitting critical context that fundamentally changes its meaning.
  • The 84.4% figure is accurate but misleading without noting concurrent therapies and low completion rates.
  • Most problematically, framing results as a "potential cure" contradicts the study's own conclusion that findings are "hypothesis-generating" and contradicts expert consensus that clinical evidence is insufficient.

Claims checked

Study presented as potential cure

Incorrect93%
The study explicitly states findings are 'hypothesis-generating and support the need for randomized controlled trials.' Expert reviews emphasize lack of clinical evidence and no major oncology organizations endorse these drugs for cancer treatment. This is not presented as a cure.

This claim may mislead readers without added context.

Study demonstrates clinical efficacy of this combination for cancer

Misleading90%
This is a self-reported observational study with 61.9% completion rate. Most patients received concurrent therapies (chemotherapy, radiation, surgery, supplements). Prior clinical trials of mebendazole alone showed all patients experienced rapid progressive disease. The evidence is insufficient for efficacy claims.

This claim may mislead readers without added context.

Nearly half of patients reporting disappearance

Misleading92%
The study reports 48.4% with 'tumor regression or no evidence of disease,' but this includes stable disease in the broader 84.4% figure. The word 'disappearance' overstates outcomes; 32.8% had no evidence of disease and 15.6% had regression, while 36.1% had stable disease.

This claim may mislead readers without added context.

The numerical values (84.4% clinical benefit ratio and ~48.4% reporting no evidence of disease or regression) match a recently circulated observational, self‑reported cohort. However the study is not a randomized clinical trial, outcomes were self‑reported and unverified, and presenting those results as a demonstrated 'cure' is misleading.

Why this verdict

  • The numerical values (84.4% clinical benefit ratio and ~48.4% reporting no evidence of disease or regression) match a recently circulated observational, self‑reported cohort.
  • However the study is not a randomized clinical trial, outcomes were self‑reported and unverified, and presenting those results as a demonstrated 'cure' is misleading.

Claims checked

These results demonstrate ivermectin and mebendazole are cures for cancer.

Incorrect93%
An uncontrolled, self‑reported observational study cannot establish cure or efficacy; independent verification and randomized controlled trials are required to demonstrate a treatment cures cancer.

This claim may mislead readers without added context.

Nearly half of patients reported disappearance (presented as potential cure).

Misleading90%
The study reported 32.8% 'no current evidence of disease' plus 15.6% 'regression', totaling about 48.4% reporting NED or regression, but these were self‑reported, not independently verified, and do not equate to proven cures.

This claim may mislead readers without added context.

A new study shows an 84.4% clinical benefit rate for ivermectin and mebendazole in cancer.

Verified92%
An observational prospective cohort published in 2026 reported a Clinical Benefit Ratio of 84.4% (103/122 or 103/197 depending on cohorts reported) based on self‑reported outcomes.

Share this result

Try DoubleChecks